Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab

Dermatol Ther. 2020 Jul;33(4):e13694. doi: 10.1111/dth.13694. Epub 2020 Jul 8.

Abstract

Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) are lymphocytic, cicatricial alopecias. Clinically, LPP presents with multifocal patchy alopecia, while FFA, considered a variant of LPP, results in hairline recession. Frontal recession in FFA may progress as far as the mid-scalp and infrequently beyond. Treatment to arrest the inflammatory process can be challenging and response variable. We report a case of recalcitrant lichen planopilaris and frontal fibrosing alopecia demonstrating significant clinical improvement after four doses of the interleukin-23 monoclonal antibody tildrakizumab.

Keywords: frontal fibrosing alopecia; lichen planopilaris; tildrakizumab.

Publication types

  • Case Reports

MeSH terms

  • Alopecia / diagnosis
  • Alopecia / drug therapy
  • Alopecia / pathology
  • Antibodies, Monoclonal, Humanized
  • Cicatrix / pathology
  • Fibrosis
  • Humans
  • Lichen Planus* / diagnosis
  • Lichen Planus* / drug therapy
  • Lichen Planus* / pathology
  • Scalp / pathology

Substances

  • Antibodies, Monoclonal, Humanized
  • tildrakizumab